ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

酢酸メゲストロール

Megestrol Acetate

HCID 11683
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
595-33-5
標準SMILES
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
分子式
C24H32O4
平均分子量
384.5 g/mol
単同位体質量
384.2300595

概要

Megestrol Acetate can cause cancer and developmental toxicity according to state or federal government labeling requirements.

名称と識別子

優先名称
Megestrol Acetate
IUPAC
[(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
現地名
酢酸メゲストロール
英語名
Megestrol acetate
分子式
C24H32O4
分子量
384.51

名称と別名

MEGESTROL ACETATE595-33-5Megestryl acetateMegaceNiagestinMegeronOvabanOvaridMegace ESMegestatBDH 1298Maygace
名称をさらに表示
酢酸メゲストロールメゲスチルニアゲスチン6-メチル-6,7-ジデヒドロ-17α-アセトキシプロゲステロンマゲスチンメゲスタットメガスメゲスチン17-アセチルオキシ-6-メチルプレグナ-4,6-ジエン-3,20-ジオンオババンメゲストリルアセタートメイガス17-アセトキシ-6-メチルプレグナ-4,6-ジエン-3,20-ジオンメゲロン6-メチル-6,7-ジデヒドロ-17-アセトキシプロゲステロン17-ヒドロキシ-6-メチルプレグナ-4,6-ジエン-3,20-ジオン=アセタートオバリドメゲストロールアセタート17α-アセトキシ-6-メチル-4,6-プレグナジエン-3,20-ジオン17α-ヒドロキシ-6-メチル-4,6-プレグナジエン-3,20-ジオン17-アセタートS4MGANia17alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dioneMEGESTROL ACETATE-D3bdh1298sc103636-MethleneProgesterone AcetateMEGESTROLACETATE,MILLEDPOWDER,USP17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
PallaceMagestinVolidanSC 10363NSC-71423MegestilMegesterol acetateSC-10363

物性

構造計算による物性

XLogP
3.1
極性表面積
60.4 Ų
水素結合供与体数
0
水素結合受容体数
4
回転可能結合数
3
重原子数
28
形式電荷
0
複雑度
820

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 2 件

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point218.0-220.0 °C
Collision Cross Section · 2 件

198.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID9040683]

180.1 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
214 °C · 214°C
沸点

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (15.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P319, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 125 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

Hazard Traits - Carcinogenicity; Developmental Toxicity

Megestrol acetate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (15.2%)

毒性情報

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Megestrol acetate

Ambiguous-DILI-concern

1

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Megestrol acetate

0.9

3.9

For treatment of endometrial carcinoma, the dosage is 40 to 320 mg/day in divided doses.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 40 mg/day, Lowest Therapeutic Dose (LTD): 0.5 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

化学と産業

薬理情報

Pharmacodynamics · 1 件

Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. These effects include induction of secretory changes in the endometrium, increase in basal body temperature, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. Mestrogel has slight glucocorticoid activity and very slight mineralocorticoid activity. This drug has no estrogenic, androgenic, or anabolic activity. The precise mechanism of megestrol’s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.

Mechanism of Action · 1 件

The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes.

Biological Half-Life34 hours
Metabolism/Metabolites · 1 件

Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.

FDA Pharmacological Classification · 2 件

MEGESTROL ACETATE

Progesterone Congeners [CS]; Progestin [EPC]

MeSH Pharmacological Classification · 2 件

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

関連反応

2 件
反応記録を作成
HRID 325279 の反応式
HRID 325279生成物として
HRID 894643 の反応式
HRID 894643反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
595-33-5
PubChem CID
11683
DTXSID
DTXSID9040683
ChEMBL
CHEMBL1201139
ChEBI
CHEBI:6723
UNII
TJ2M0FR8ES
EC Number
209-864-5
Nikkaji
J6.777F
431.17 °C · 431.17°C (rough estimate)
比旋光度
24 · D24 +5° (chloroform)
比重(密度)
1.0474 · 1.0474 (rough estimate)
屈折率
11 ° · 11 ° (C=2, CHCl3)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
水にほとんど溶けず、アセトンに溶け、アルコールにやや溶けにくい。
外見
Solid
色
白い
Merck
14 · 14,5805
BRN
1917291 · 1917291
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
SMILES
C1(=O)C=C2[C@](C)(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)CC3)C=C2C
CAS データベース
595 · 595-33-5(CAS DataBase Reference)
NISTの化学物質情報
Megestrol acetate(595-33-5)
EPAの化学物質情報
Megestrol acetate (595-33-5)

化学的性質

化学的特性Crystalline Solid

4-Oct-18

安全データ

wgk
3
rtecs
TU4075000
毒性
LD50 intravenous in mouse: 56mg/kg
hs_code
29372390
risk_code
40-48
hazard_code
Xn
safety_code
22-24/25

Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.

Absorption, Distribution and Excretion · 2 件

Variable, but well absorbed orally.

The major route of drug elimination in humans is urine. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.

用途と製造

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
応用分野 · 3 件

説明Megestrol Acetate is the acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. It is frequently used in the treatment of patients with metastatic breast cancer. It is generally well tolerated, except that it may cause undesirable weight gain. Subsequently, it was shown that megestrol acetate produced weight gain in a variety of cachectic cancer patients. Significant reduction inserum levels of IL-1a and b,IL-2,IL-6, and TNF-o were observed in cancer patientstreated with megestrol acetate which may bear on the mechanism of improved appetite and body weight gain.It has also been postulated that the effect is, at least in part,mediated by NPY,a potent central appetite stimulant.

使用Megestrol acetate (Megace), a semi-synthetic progestational steroid, is the most effective known appetite stimulant at present. Previously used in patients with cancer and acquired immunodeficiency syndrome, only a few studies have considered the applicability of this drug in malnourished older persons. Megestrol acetate is useful if profound anorexia is the main manifestation of cachexia and if expected survival is weeks to months. Megace has been shown to significantly increase appetite, but not survival. In patients with a shorter predicted survival, a brief course of corticosteroids may be useful to stimulate appetite and have positive effects on nausea, pain, and asthenia.

一般的な説明Megestrol acetate, 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate(Megace), is a progestin used primarily for the palliativemanagement of recurrent, inoperable, or metastatic endometrialor breast carcinoma. Megestrol acetate has also beenindicated for appetite enhancement in patients with AIDS.The biochemical basis for this use of megestrol is unclear.

上流・下流製品情報

上流原料

17α-ヒドロキシプロゲステロン水素化ほう素カリウム16,17-エポキシプロゲステロン1,4-ベンゾキノンアルミニウムtert-ブトキシド

下流製品

17-Hydroxy-6-methylpregn-4-ene-3,20-dione 17-acetate